Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient’s T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them. However, clinical data show that more than 50% … Read more